DJI48,977.92-1.05%
GDAXI24,822.62-1.83%
GSPC6,878.88-0.43%
HSI26,059.85-2.14%
IXIC22,668.21-0.92%
N22558,057.24-1.35%
AAPL264.18-3.21%
AMZN210.00+1.00%
CL71.80+7.13%
EURUSD1.1736-0.69%
GBPUSD1.3411-0.53%
GC5,405.60+3.01%
GOOG311.43+1.39%
JPM300.30-1.90%
META648.18-1.34%
MSFT392.74-2.24%
NVDA177.19-4.16%
TSLA402.51-1.49%
DJI48,977.92-1.05%
GDAXI24,822.62-1.83%
GSPC6,878.88-0.43%
HSI26,059.85-2.14%
IXIC22,668.21-0.92%
N22558,057.24-1.35%
AAPL264.18-3.21%
AMZN210.00+1.00%
CL71.80+7.13%
EURUSD1.1736-0.69%
GBPUSD1.3411-0.53%
GC5,405.60+3.01%
GOOG311.43+1.39%
JPM300.30-1.90%
META648.18-1.34%
MSFT392.74-2.24%
NVDA177.19-4.16%
TSLA402.51-1.49%
DJI48,977.92-1.05%
GDAXI24,822.62-1.83%
GSPC6,878.88-0.43%
HSI26,059.85-2.14%
IXIC22,668.21-0.92%
N22558,057.24-1.35%
AAPL264.18-3.21%
AMZN210.00+1.00%
CL71.80+7.13%
EURUSD1.1736-0.69%
GBPUSD1.3411-0.53%
GC5,405.60+3.01%
GOOG311.43+1.39%
JPM300.30-1.90%
META648.18-1.34%
MSFT392.74-2.24%
NVDA177.19-4.16%
TSLA402.51-1.49%
LIVE
CHE NZZ Finanzen DE

Roche schafft den Genussschein ab – was Anleger wissen müssen

Die stimmrechtslosen Beteiligungspapiere werden bald durch Partizipationsscheine ersetzt. Damit verschafft sich der Pharmakonzern auch mehr Spielraum bei der Kapitalaufnahme.

Mar 01, 2026 &03300101202631; 04:30 UTC www.nzz.ch
Read original on www.nzz.ch ↗
Positive for markets
Sentiment score: +75/100
Moderate impact Medium-term (weeks)
WHAT THIS MEANS
Roche is replacing non-voting participation certificates with new participation certificates, enhancing its capital raising flexibility. This move could improve financial management and support growth initiatives, though it may alter shareholder dynamics.
AI CONFIDENCE
80% Very high
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
ROG
ROGStock
Expected to rise
The shift to participation certificates provides Roche with greater capital raising options, potentially boosting financial health and long-term value creation.
PRICE HISTORY
Loading chart...
SUGGESTED ACTION
Consider accumulating Roche stock as the improved capital structure may lead to better financial performance and stock appreciation over the medium term.
KEY SIGNALS
Capital structure optimizationEnhanced financing flexibilityShareholder rights adjustment
SECTORS INVOLVED
Pharmaceuticals
Analysis generated on Mar 01, 2026 at 06:08 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by NZZ Finanzen. Always conduct your own research and consult a qualified financial advisor before making investment decisions.